MAR 16, 2016 10:30 AM PDT

Future of Psychopharmacology: Is New Treatment Innovation "Dead?"

Speaker
  • Stephen Stahl, PhD

    Adjunct Professor of Psychiatry, University of California, San Diego, Honorary Visiting Senior Fellow, University of Cambridge, UK, Chairman, Neuroscience Education Institute (NEI), Editor-in
    BIOGRAPHY

Abstract

Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology!  
What’s going on in our field? 

  • Priorities of Big Pharma shifting away from CNS and especially from psychiatry
  • Failed clinical trials littering the landscape
  • Even known drugs don’t work in psychiatric trials
  • Broken clinical trial apparatus
  • Iterative step-wise improvements or ‘me-too’ agents not reimbursed
  • Aggressive cost controls
  • No new validated targets

Learning objectives - 

  • Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry
  • Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders
  • Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers

MAR 16, 2016 10:30 AM PDT

Future of Psychopharmacology: Is New Treatment Innovation "Dead?"